Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | ILK | Q13418 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424613 | 0.93 | AURKA (0.55) | FLT3AURKACSF1RKITFLT4 | |
| SCHEMBL4511733 | 0.80 | KDM1A (0.49) | ILKMAOAKDRFGFR1FLT1 | |
| SCHEMBL4420328 | 0.79 | AURKA (0.41) | FLT3AURKACSF1RKITFLT4 | |
| SCHEMBL4420331 | 0.79 | AURKA (0.41) | FLT3AURKACSF1RKITFLT4 | |
| SCHEMBL4422595 | 0.79 | KDM4E (0.47) | FLT3AURKACSF1RKITFLT4 | |
| SCHEMBL13841371 | 0.79 | NPC1 (0.57) | ILKKDM4EMAOASRCKDR | |
| SCHEMBL4426235 | 0.78 | BRAF (0.46) | FLT3AURKACSF1RKITFLT4 | |
| SCHEMBL4500426 | 0.77 | DRD3 (0.55) | TSHRFLT3AURKACSF1RKIT | |
| SCHEMBL15483915 | 0.77 | ILK (0.55) | TSHRAURKAILKKDM4EMAOA | |
| SCHEMBL4507750 | 0.77 | KDM4E (0.61) | TSHRILKKDM4EMAOASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | claimed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | claimed |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| EP-1458394-B1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | GSK3A, GSK3B, PYGB | TSHR 4367/4885FLT3 4423/4885AURKA 606/4885 |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | GSK3A, GSK3B, PSEN1 | TSHR 4461/4885FLT3 4197/4885AURKA 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.